Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Ipriflavone improves BMD in postmenopausal women with osteoporosis

Publish date:: July 1, 2020

Key clinical point: Ipriflavone significantly increases bone mineral density (BMD) in postmenopausal women with osteoporosis.

Major finding: In a random-effects model, patients receiving ipriflavone had a greater improvement in BMD of the lumbar spine compared with those receiving placebo (standardized mean difference, 0.35; P = .009). Adverse drug withdrawal events were comparable between groups.

Study details: A meta-analysis of 11 randomized control trials including 1,605 patients.

Disclosures: This study was supported by the Natural Science Foundation of China, Sichuan Project, Sichuan University Project, and Shenzhen Projects. The authors declared no conflicts of interest.

Citation:

Hu Q et al. Pharmacol Res. 2020 May 12. doi: 10.1016/j.phrs.2020.104860

This Week's Must Reads

Higher dose maximizes effects of magnesium sulfate for obese women,

Microplastics permeate human placentas,

One in five gestational carriers do not meet ASRM criteria,

Gender surgical outcomes differ following puberty suppression,

COVID-19 vaccine found effective but doctors watching for reactions, adverse events,

Must Reads in Osteoporosis

Risk factors for osteoporosis in CHF patients,

Switching to denosumab prevents osteoporosis progression in postmenopausal women with T2D,

Higher prevalence of periapical lesions in patients with osteoporosis,

Psoriasis tied to increased risk for osteoporosis,

BMD and bone turnover after gastric bypass vs. sleeve gastrectomy,